Neil Crabb, chief executive of () caught up with Proactive's Andrew Scott following the release of their half-year report.
Frontier’s portfolio includes AI drug researcher Exscientia which secured a €15mln strategic investment from drug discovery company Evotec while foodtech company Nandi Protein raised £1mln in the period.
Crabb says they’re seeing strong interest across the board in their its portfolio which he reckons reflects the success of their strategy to take stakes in companies which are at a very early stage of the commercialisation process.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE